Endevica Bio Announces First Patient Dosing in Phase 2 Trial in Patients with Stage 4 Metastatic Colorectal Cancer

Endevica Bio Announces First Patient Dosing in Phase 2 Trial in Patients with Stage 4 Metastatic Colorectal Cancer

NORTHBROOK, Ill., April 17, 2025 /PRNewswire/ -- Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug TCMCB07 (B07) to prevent…

Trial Combines Binimetinib and Crizotinib in RAS-Driven Colorectal Cancer

In the relentless pursuit of more effective treatments for colorectal cancer (CRC), a groundbreaking study has recently shed light on the challenges faced when targeting RAS mutations, which remain some of the most elusive drivers of this disease. Published in BMC Cancer, the Phase Ia/b trial known as MErCuRIC represents a comprehensive effort to evaluate the dual inhibition of MEK1/2 and MET pathways using binimetinib and crizotinib, respective…